Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pemetrexed + donor-derived NK cell infusion
- Development stage
- Unknown
- Modality
- Adoptive Cell Transfer → Cell Therapies, Small Molecules
- Administration
- Intravenous
01
Overview
Pemetrexed is a folate antimetabolite chemotherapy agent that inhibits key enzymes involved in nucleotide synthesis, thereby disrupting DNA replication and repair in cancer cells. Donor-derived natural killer (NK) cell infusion is a form of adoptive cellular immunotherapy, where allogeneic NK cells are administered to the patient to enhance anti-tumor immune responses. The combination of pemetrexed with donor-derived NK cell infusion aims to leverage both direct cytotoxic effects on tumor cells and enhanced immune-mediated tumor killing. Pemetrexed has been shown to sensitize non-small-cell lung cancer (NSCLC) cells to cytotoxic immune cells by modulating the expression of immune-regulatory molecules such as PD-L1 and UL16-binding proteins (ULBP), which are ligands for the activating receptor NKG2D on NK cells[1][5]. This combination may improve anti-tumor efficacy compared to either treatment alone.
- Other names
- pemetrexed plus donor-derived natural killer cell infusionpemetrexed and donor NK cell therapy
02
Targets
DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)
Beyond the preview
Go deeper on pemetrexed + donor-derived NK cell infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pemetrexed + donor-derived NK cell infusion.